US20230147519A1 - Wound debridement by irrigation with ultrasonically activated microbubbles - Google Patents
Wound debridement by irrigation with ultrasonically activated microbubbles Download PDFInfo
- Publication number
- US20230147519A1 US20230147519A1 US18/091,149 US202218091149A US2023147519A1 US 20230147519 A1 US20230147519 A1 US 20230147519A1 US 202218091149 A US202218091149 A US 202218091149A US 2023147519 A1 US2023147519 A1 US 2023147519A1
- Authority
- US
- United States
- Prior art keywords
- fluid
- micro
- tissue site
- bubbles
- dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001804 debridement Methods 0.000 title description 32
- 230000002262 irrigation Effects 0.000 title 1
- 238000003973 irrigation Methods 0.000 title 1
- 239000012530 fluid Substances 0.000 claims abstract description 110
- 238000000034 method Methods 0.000 claims description 30
- 230000001338 necrotic effect Effects 0.000 claims description 15
- 239000006260 foam Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 8
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 238000005201 scrubbing Methods 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 description 94
- 206010052428 Wound Diseases 0.000 description 33
- 208000027418 Wounds and injury Diseases 0.000 description 31
- 238000002560 therapeutic procedure Methods 0.000 description 29
- 239000000463 material Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 8
- 239000011148 porous material Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000002358 autolytic effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 5
- 210000000416 exudates and transudate Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000013618 particulate matter Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000006261 foam material Substances 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004633 polyglycolic acid Substances 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229920002614 Polyether block amide Polymers 0.000 description 2
- 229920005830 Polyurethane Foam Polymers 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 239000011496 polyurethane foam Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920001247 Reticulated foam Polymers 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000009581 negative-pressure wound therapy Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3203—Fluid jet cutting instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00068—Accessories for dressings specially adapted for application or removal of fluid, e.g. irrigation or drainage of wounds, under-pressure wound-therapy
-
- A61F13/05—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/84—Drainage tubes; Aspiration tips
- A61M1/85—Drainage tubes; Aspiration tips with gas or fluid supply means, e.g. for supplying rinsing fluids or anticoagulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/91—Suction aspects of the dressing
- A61M1/915—Constructional details of the pressure distribution manifold
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/92—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with liquid supply means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/94—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with gas supply means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0229—Devices operating in a closed circuit, i.e. recycling the irrigating fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
- A61B2017/22005—Effects, e.g. on tissue
- A61B2017/22007—Cavitation or pseudocavitation, i.e. creation of gas bubbles generating a secondary shock wave when collapsing
- A61B2017/22008—Cavitation or pseudocavitation, i.e. creation of gas bubbles generating a secondary shock wave when collapsing used or promoted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22082—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
- A61B2017/22089—Gas-bubbles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B2017/320004—Surgical cutting instruments abrasive
- A61B2017/320008—Scrapers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/320068—Surgical cutting instruments using mechanical vibrations, e.g. ultrasonic
- A61B2017/320084—Irrigation sleeves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3203—Fluid jet cutting instruments
- A61B2017/32032—Fluid jet cutting instruments using cavitation of the fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/0017—Wound bandages possibility of applying fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/0017—Wound bandages possibility of applying fluid
- A61F2013/00174—Wound bandages possibility of applying fluid possibility of applying pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/0028—Wound bandages applying of mechanical pressure; passive massage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00357—Wound bandages implanted wound fillings or covers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00582—Properties of backing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/10—Ultra-violet radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/10—Apparatus features
- A61L2202/11—Apparatus for generating biocidal substances, e.g. vaporisers, UV lamps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0275—Pulsating jets; Vibrating nozzles
Definitions
- the invention set forth in the appended claims relates generally to tissue treatment systems and more particularly, but without limitation, to debridement devices, systems, and methods suitable for debriding a tissue site.
- Negative-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.
- debridement of a tissue site can be highly beneficial for new tissue growth.
- Debridement may refer to a process for removing dead, damaged, or infected tissue from a tissue site for improving the healing potential of healthy tissue remaining at the tissue site.
- Several factors may make proper debridement difficult, such as challenging wound locations, immobile patients, and environmental constraints. Further, debridement may often be painful for the patient, and in some circumstances may also require a high level of skill from the caregiver, thereby presenting additional challenges. Additionally, debridement methods that are less painful to patients may be relatively slow processes. Therefore, improvements to debridement devices, systems, and methods that may reduce the amount of time to debride a tissue site as well as reduce the risks of pain for the patient or damage to healthy tissue associated with conventional methodologies may be desirable.
- a system for treating a tissue site may include a dressing, a negative-pressure source fluidly coupled to the dressing, a fluid source, and an ultrasonic bubble generator.
- the ultrasonic bubble generator may be fluidly coupled to the fluid source and to the dressing and may be configured to generate micro-bubbles and ultrasonic waves in a fluid from the fluid source.
- a method for debriding necrotic tissue from a tissue site may include coupling a fluid source to the tissue site, supplying a fluid from the fluid source to an ultrasonic bubble generator, generating micro-bubbles and ultrasonic waves in the fluid with the ultrasonic bubble generator, and delivering the micro-bubbles and ultrasonic waves to the necrotic tissue.
- the ultrasonic bubble generator may further include an ultra-violet light source.
- the method may further include coupling a negative-pressure source to a dressing.
- FIG. 1 is a schematic diagram of an example embodiment of negative-pressure therapy system that can deliver ultrasonically-activated micro-bubbles in accordance with this specification.
- FIG. 2 is a perspective view illustrating additional details that may be associated with some example embodiments of the negative-pressure therapy system of FIG. 1 .
- the tissue site 102 may include, without limitation, any irregularity with a tissue, such as an open wound, surgical incision, or diseased tissue.
- the therapy system 100 is presented in the context of a tissue site 102 that includes a wound 104 , which is through the epidermis 106 , or generally skin, and the dermis 108 and reaching into a hypodermis, or subcutaneous tissue 110 .
- the therapy system 100 may be used to treat a wound of any depth, as well as many different types of wounds including open wounds or other tissue sites.
- the tissue site 102 may be the bodily tissue of any human, animal, or other organism, including bone tissue, adipose tissue, muscle tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, ligaments, or any other tissue. Treatment of the tissue site 102 may include removal of fluids, for example, exudate or ascites.
- tissue site in this context broadly refers to a wound or defect located on or within tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments.
- a wound may include chronic, acute, traumatic, subacute, and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps, and grafts, for example.
- tissue site may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it may be desirable to add or promote the growth of additional tissue. For example, negative pressure may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another tissue location.
- the terms “debride,” “debriding,” and “debridement,” relate to the act of removing or the removal of undesirable tissue, such as, eschar, necrotic, damaged, infected, contaminated, or adherent tissue, or foreign material from a tissue site.
- tissue such as, eschar, necrotic, damaged, infected, contaminated, or adherent tissue, or foreign material from a tissue site.
- methods of debridement may be employed to treat a wound 104 having necrotic tissue 112 , including surgical debridement, mechanical debridement, chemical or enzymatic debridement, and autolytic debridement.
- Chemical, or enzymatic, debridement entails the use of chemical enzymes to convert the necrotic tissue to slough. Chemical debridement may be fast-acting and cause minimal damage to healthy tissue if the chemicals are applied properly. However, chemical debridement has disadvantages as well. The process may be expensive and traditional chemical debridement methods and systems, such as low pH systems, may be painful to a patient. Other debriding agents, such as papain, may have other health implications and only have limited usage that is restricted by law. Other agents may be used, such as medical grade honey, but can become quickly mobile in the presence of fluid, such as wound exudate, and an applied negative pressure.
- Autolytic debridement or autolysis, entails the use of the body's own enzymes and white blood cells, along with moisture, to hydrate and liquefy the necrotic tissue 112 and slough. Since autolytic debridement is a naturally occurring process, it is relatively painless and does not risk damage to healthy tissue. Further, autolytic debridement does not require wound fluid to remain in contact with the necrotic tissue 112 , and can be facilitated by the use of films, hydrocolloids, and hydrogels. A disadvantage of autolytic debridement is that autolytic debridement is slower than other types of debridement, rendering the wound susceptible to infection.
- the therapy system 100 may address these outstanding needs and others.
- the therapy system 100 may provide a low-pain alternative for enhanced debridement and healing of wounds that can be used in conjunction with negative-pressure treatment.
- the wound 104 may include necrotic tissue 112 , and in many instances, it may be desirable to remove the necrotic tissue 112 in order to promote healing of the wound 104 .
- the illustrative, non-limiting embodiment shows the therapy system 100 in the context of the wound 104 having a localized, or discrete area, of necrotic tissue 112 within the wound.
- the therapy system 100 may be used in broader contexts, including with any tissue site having undesirable tissue.
- Such undesirable tissue may include, necrotic, damaged, infected, contaminated, or adherent tissue, foreign material within the wound 104 , and may include a layer of necrotic tissue 112 that covers the entire surface of the wound 104 .
- the therapy system 100 may include a dressing, a negative-pressure source, a fluid source, and a micro-bubble source.
- a dressing 114 may be fluidly coupled to a negative-pressure source 116 , a fluid source 117 , and a micro-bubble subsystem 118 , as illustrated in FIG. 1 .
- the therapy system 100 may also include a container for supplying fluid as well as collecting exudates, such as a container 120 , coupled to the dressing 114 and to the negative-pressure source 116 .
- components of the therapy system 100 may be coupled directly or indirectly.
- the negative-pressure source 116 may be directly coupled to components of the micro-bubble subsystem 118 and the container 120 , and indirectly coupled to the dressing 114 through the micro-bubble subsystem 118 and the container 120 .
- components may be coupled by virtue of physical proximity, being integral to a single structure, or being formed from the same piece of material. Coupling may also include mechanical, thermal, electrical, or chemical coupling (such as a chemical bond) in some contexts.
- Components may also be fluidly coupled to each other to provide a path for transferring fluids (i.e., liquid and/or gas) between the components.
- components may be fluidly coupled through a tube.
- a tube is an elongated, cylindrical structure with some flexibility, but the geometry and rigidity may vary.
- a fluid conductor may also be integrally molded into a component in some embodiments.
- the dressing 114 may be placed within, over, on, or otherwise proximate to the tissue site 102 .
- the dressing 114 may be sealed to tissue near the tissue site 102 .
- the dressing 114 may be sealed to undamaged epidermis peripheral to the tissue site 102 .
- the dressing 114 can provide a sealed therapeutic environment proximate to the tissue site 102 , substantially isolated from the external environment, and the negative-pressure source 116 can reduce the pressure in the sealed therapeutic environment. Negative pressure applied across the tissue site 102 through the dressing 114 in the sealed therapeutic environment can induce macro-strain and micro-strain in the tissue site, as well as remove exudate and other fluid from the tissue site 102 , which can be collected in the container 120 .
- the fluid mechanics of using a negative-pressure source to reduce pressure in another component or location, such as within a sealed therapeutic environment can be mathematically complex.
- the basic principles of fluid mechanics applicable to negative-pressure therapy and instillation are generally well-known to those skilled in the art.
- fluid flows toward lower pressure along a fluid path.
- downstream typically implies something in a fluid path relatively closer to a source of negative pressure or further away from a source of positive pressure; conversely, the term “upstream” implies something relatively further away from a source of negative pressure or closer to a source of positive pressure.
- inlet or “outlet” in such a frame of reference, and the process of reducing pressure may be described illustratively herein as “delivering,” “distributing,” or “generating” reduced pressure, for example. This orientation is generally presumed for purposes of describing various features and components herein.
- Negative pressure generally refers to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment external to a sealed therapeutic environment provided by the dressing 114 .
- the local ambient pressure may also be the atmospheric pressure at which a tissue site is located.
- negative pressure may be a pressure less than a hydrostatic pressure associated with tissue at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures.
- references to increases in negative pressure typically refer to a decrease in absolute pressure, while decreases in negative pressure typically refer to an increase in absolute pressure.
- a negative-pressure source such as the negative-pressure source 116
- a negative-pressure source may be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate negative-pressure therapy.
- the pressure is generally a low vacuum, also commonly referred to as a rough vacuum, between ⁇ 5 mm Hg ( ⁇ 667 Pa) and ⁇ 500 mm Hg ( ⁇ 66.7 kPa).
- a rough vacuum between ⁇ 5 mm Hg ( ⁇ 667 Pa) and ⁇ 500 mm Hg ( ⁇ 66.7 kPa).
- Common therapeutic ranges are between ⁇ 75 mm Hg ( ⁇ 9.9 kPa) and ⁇ 300 mm Hg ( ⁇ 39.9 kPa).
- the fluid source 117 may be housed within or used in conjunction with other components to facilitate movement of a fluid.
- the fluid source 117 may be a fluid pump, for example a peristaltic pump.
- the fluid source 117 may be a fluid reservoir, which may store and deliver fluid.
- the fluid source 117 such as a fluid pump or a fluid reservoir, may include a container, such as a canister, pouch, or other storage component.
- the fluid source 117 may be a fluid pump that helps supply the micro-bubble subsystem 118 with the fluid that may ultimately be delivered to a tissue site.
- the dressing 114 may include a manifold 122 and a drape 124 .
- the dressing 114 may also include an attachment device 126 that affixes the drape 124 to the epidermis 106 of the patient.
- the drape 124 may also include an adhesive surface that seals directly against the epidermis 106 of the patient without the need for an attachment device.
- the manifold 122 may be positioned between a tissue-facing surface of the drape 124 and the tissue site 102 .
- the manifold 122 may generally include any substance or structure providing a plurality of pathways adapted to collect or distribute fluid across a tissue site.
- a manifold may be adapted to receive negative pressure from a source and distribute negative pressure through multiple apertures across a tissue site, which may have the effect of collecting fluid from across a tissue site and drawing the fluid toward the source.
- the fluid path may be reversed or a secondary fluid path may be provided to facilitate distributing fluid across a tissue site.
- the pathways of a manifold may be interconnected to improve distribution or collection of fluids across a tissue site.
- cellular foam, open-cell foam, reticulated foam, porous tissue collections, and other porous material such as gauze or felted mat generally include pores, edges, and/or walls adapted to form interconnected fluid pathways.
- Liquids, gels, and other foams may also include or be cured to include apertures and fluid pathways.
- a manifold may be a porous foam material having interconnected cells or pores adapted to distribute negative pressure across a tissue site.
- the foam material may be either hydrophobic or hydrophilic.
- the pore size of a foam material may vary according to needs of a prescribed therapy.
- the manifold 122 may include a wound filler, which may be a foam having a large pore size or may be a perforated felted foam.
- the pores or perforations of the wound filler may be in the range of 3-7 millimeters (mm) in diameter, and preferably about 5 mm in diameter.
- the tensile strength of the manifold 122 may also vary according to needs of a prescribed therapy. For example, the tensile strength of a foam may be increased for instillation of topical treatment solutions.
- the manifold 122 may be an open-cell, reticulated polyurethane foam such as GranuFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Tex.; in other embodiments the manifold 122 may be an open-cell, reticulated polyurethane foam such as a VeraFlo® foam, also available from Kinetic Concepts, Inc., of San Antonio, Tex.
- the manifold 122 may also wick fluid away from a tissue site, while continuing to distribute negative pressure to the tissue site.
- the wicking properties of the manifold 122 may draw fluid away from a tissue site by capillary flow or other wicking mechanisms.
- An example of a hydrophilic foam is a polyvinyl alcohol, open-cell foam such as V.A.C. WhiteFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Tex.
- Other hydrophilic foams may include those made from polyether.
- Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.
- the manifold 122 may be constructed from bioresorbable materials. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, and capralactones.
- the manifold 122 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the manifold 122 to promote cell-growth.
- a scaffold is generally a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth.
- Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.
- the drape 124 may provide a bacterial barrier and protection from physical trauma.
- the drape 124 may also be constructed from a material that can reduce evaporative losses and provide a fluid seal between two components or two environments, such as between a therapeutic environment and a local external environment.
- the drape 124 may be, for example, an elastomeric film or membrane that can provide a seal adequate to maintain a negative pressure at a tissue site for a given negative-pressure source.
- the drape 124 may be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquid. Such drapes typically have a thickness in the range of 25-50 microns. For permeable materials, the permeability generally should be low enough that a desired negative pressure may be maintained.
- an attachment device 126 may be used to attach the drape 124 to an attachment surface, such as undamaged epidermis, a gasket, or another cover.
- the attachment device 126 may take many forms.
- an attachment device may be a medically-acceptable, pressure-sensitive adhesive that extends about a periphery, a portion, or the entire drape 124 .
- some or all of the drape 124 may be coated with an acrylic adhesive having a coating weight between 25-65 grams per square meter (g.s.m.). Thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve the seal and reduce leaks.
- Other example embodiments of an attachment device may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, or organogel.
- the negative pressure provided by the negative-pressure source 116 may be delivered through a conduit 128 to a negative-pressure interface 130 , which may be an elbow port 132 .
- the negative-pressure interface 130 is a T.R.A.C.® Pad or Sensa T.R.A.C.® Pad available from KCI of San Antonio, Tex.
- the negative-pressure interface 130 allows the negative pressure to be delivered to the drape 124 and realized within an interior portion of the drape 124 and the manifold 122 .
- the elbow port 132 extends through the drape 124 to the manifold 122 , but numerous arrangements are possible.
- the container 120 is representative of a container, canister, pouch, or other storage component, which can be used to manage exudate and other fluid withdrawn from a tissue site. In many environments, a rigid container may be preferred or required for collecting, storing, and disposing of fluid. In some preferred embodiments, the container 120 may be positioned in fluid communication between the negative-pressure source 116 and the dressing 114 to collect fluid drawn from a tissue site. The container 120 may also include features that enable filtering of the effluent that is withdrawn from the dressing 114 and tissue site 102 . In some embodiments, the container 120 may attach to the negative-pressure source 116 , as illustrated in FIG. 1 .
- the container 120 may include multiple ports and connection interfaces for integration with the negative-pressure source 116 , the fluid source 117 , and the other components of the therapy system 100 .
- the container 120 may have two outlets, one of which may be for fluidly connecting the container 120 to the fluid source 117 , and the second of which may be for fluidly connecting the container 120 to the negative-pressure source 116 .
- the micro-bubble subsystem 118 may include a UV light sterilizer 136 and an ultrasonic bubble generator 138 .
- the UV light sterilizer 136 may be positioned in fluid connection between the negative-pressure source 116 and the ultrasonic bubble generator 138 .
- the micro-bubble subsystem 118 may be fluidly connected to the negative-pressure source 116 and the dressing 114 by the supply conduit 140 .
- the micro-bubble subsystem 118 may be in close physical proximity to the dressing 114 , or optionally incorporated as part of the dressing 114 . In other embodiments, some or all of the components of the micro-bubble subsystem 118 may be incorporated within the negative-pressure source 116 .
- the fluid may pass through the UV light sterilizer 136 .
- the UV light sterilizer 136 may contain a UV light source, which may dose the fluid passing through the UV light sterilizer 136 with UV light to kill any pathogens that may be in the fluid. Once the fluid has passed through the UV light sterilizer 136 , the fluid may be delivered to the ultrasonic bubble generator 138 through supply conduit 140 .
- the ultrasonic bubble generator 138 may function to generate both micro-bubbles and an ultrasonic waveform in a fluid.
- the ultrasonic bubble generator 138 may be an apparatus for generating an output flow of liquid, including an acoustic transducer for introducing acoustic energy into the liquid and a gas bubble generator for generating gas bubbles within the liquid, as described in U.S. Patent Application Publication No. US 2012/0227761 A1, which is hereby incorporated by reference in its entirety.
- fluid may be delivered from the UV light sterilizer 136 through supply conduit 140 to the ultrasonic bubble generator 138 .
- the ultrasonic bubble generator 138 may generate and inject gas bubbles within the fluid. While the micro-bubbles may be generated in a range of sizes, the micro-bubbles may typically be approximately 15-200 micrometers ( ⁇ m) in diameter.
- the ultrasonic bubble generator 138 may then generate an ultrasonic waveform that may be conducted through the fluid as it flows through the ultrasonic bubble generator 138 .
- the ultrasonic bubble generator 138 may include a transducer that emits acoustic energy. The acoustic energy may be emitted as intermittent pulses. Referring also to FIG.
- micro-bubbles 202 may undergo significant deformation which may manifest itself as a ripple 204 at the gas/liquid interface.
- the micro-bubble can exert a scrubbing action on surfaces it touches as the micro-bubble 206 is deformed, and the turbulence formed around the micro-bubble may also cause the micro-bubble to be drawn to surfaces and into cracks and crevices, such as deformities at a tissue site.
- the manifold 122 may be tailored to cause minimal attenuation of the ultrasonic energy generated by the micro-bubble source 118 .
- the manifold 122 may be largely constructed from polymers that are hydrophilic, which may contain water or be configured to absorb water.
- hydrophilic polymers may include poly hydroxy ethyl methacrylate, copolymer of N-vinyl pyrrolidone and 2-hydroxy ethyl methacrylate, terpolymer based on glycerol methacrylate, copolymer of N-vinyl pyrrolidone and methyl methacrylate, as well as polymethyl methacrylate (PMMA).
- the manifold 122 may be constructed from hydrophilic polyurethane polymers, such as TECOPHILIC hydrophilic polyurethanes available from The Lubrizol Corp. of Wickliffe, Ohio, which in extrusion grade formulations, may absorb water up to 100% of the weight of dry resin (900% of weight of dry resin for hydrogel grades) while retaining structural integrity.
- the manifold 122 may be formed from one of the hydrophilic polymers listed above into a porous or foamed structure with pores measuring approximately 5-10 mm in diameter, which may minimize the number of struts that could interfere with the passage of bubbles.
- the manifold 122 may be formed from one of the hydrophilic polymers formed into a perforated sheet having protrusions on one side.
- the protrusions may be spaced about 5-10 mm apart from each other, and may be hemispherical or polygonal in shape. The protrusions may act as spacers between the wound 104 and the drape 124 .
- the therapy system 100 presented in FIG. 1 may also include a second interface, such as fluid-delivery interface 142 .
- the fluid-delivery interface 142 may be fluidly coupled to the dressing 114 and may pass through a hole cut in the drape 124 .
- the hole cut in the drape for the fluid-delivery interface 142 may be separated as far apart as possible from the location or other hole cut in the drape through which the negative-pressure interface 130 may pass.
- the fluid-delivery interface 142 may allow for a fluid to be delivered by the therapy system 100 through the drape 124 and to the manifold 122 and the tissue site 102 .
- the fluid-delivery interface 142 may include an inlet pad.
- the inlet pad may be a non-dampening material or a material that is not sound-absorbing.
- the inlet pad may be an elastomer.
- the inlet pad may be an elastic polymer, such as polyurethane, thermoplastic elastomers, polyether block amide (PEBAX), polyisoprene, polychloroprene, chlorosulphonated polythene, and polyisobutylene, blends and copolymers.
- composition of the fluid may vary according to a prescribed therapy, but examples of solutions that may be suitable for some prescriptions include a saline solution with a low level of surfactant, such as ⁇ 0.1%, and more typically 0.015%.
- surfactants may include Pluronic F68, polyolefin oxides, and polyolefin glycols.
- the therapy system 100 may also include a particulate filter 134 , which may be positioned in fluid communication between the container 120 and/or the negative-pressure source 116 and the dressing 114 .
- the particulate filter 134 may function to remove particulate matter from the effluent that has circulated through the dressing 114 .
- fluid delivered to the dressing 114 and to the tissue site 102 may be drawn out of the dressing 114 through the negative-pressure interface 130 and transported through negative-pressure conduit 128 to the particulate filter 134 .
- the fluid may be filtered to remove particulate matter in the particulate filter 134 , before being recollected in the container 120 .
- the negative-pressure source 116 may pump fluid, such as a saline solution through the supply conduit 140 to a UV light sterilization unit, such as UV light sterilizer 136 .
- fluid such as a saline solution
- UV light sterilizer 136 a UV light sterilization unit
- the fluid may continue through supply conduit 140 to the ultrasonic bubble generator 138 , where micro-bubbles may be generated in the fluid, followed by the fluid and micro-bubbles being activated by ultrasonic energy applied by the ultrasonic bubble generator 138 .
- the activated fluid may then pass through the fluid-delivery interface 142 and into the dressing 114 .
- the activated fluid may then pass through the manifold 122 and reach the wound 104 , where the activated fluid may debride necrotic tissue 112 .
- the remaining effluent may be drawn out of the dressing 114 by negative pressure applied to the dressing 114 and tissue site 102 by the negative-pressure source 116 .
- the effluent may be drawn from the wound 104 , through the manifold 122 , and out of the dressing 114 through the negative-pressure interface 130 .
- the effluent may then pass through negative-pressure conduit 128 to the particulate filter 134 , where particulate matter may be filtered out of the effluent.
- the filtered fluid may then be collected by the container 120 before being recirculated by the negative-pressure source 116 through the UV light sterilizer 136 and ultrasonic bubble generator 138 to the wound 104 .
- a therapy system described above may provide a low-pain, clean method to achieve an alternative form of mechanical debridement.
- the therapy system can keep a wound enclosed, thus reducing the possible risk of infection, and can also store any particulate matter in a convenient location that may be easily disposed.
- the therapy system may also reduce the risk of contaminating the environment external to a wound with potentially infectious matter, and can also keep odors contained.
Abstract
Description
- The present invention is a continuation of U.S. patent application Ser. No. 16/595,763, filed Oct. 8, 2019, which is a continuation of U.S. patent application Ser. No. 15/147,666, filed May 5, 2016, now U.S. Pat. No. 10,471,190, which claims the benefit under 35 U.S.C. § 119(e), of the filing of U.S. Provisional Patent Application Ser. No. 62/158,630, filed May 8, 2015, all of which are incorporated herein by reference for all purposes.
- The invention set forth in the appended claims relates generally to tissue treatment systems and more particularly, but without limitation, to debridement devices, systems, and methods suitable for debriding a tissue site.
- Clinical studies and practice have shown that reducing pressure in proximity to a tissue site can augment and accelerate growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but it has proven particularly advantageous for treating wounds. Regardless of the etiology of a wound, whether trauma, surgery, or another cause, proper care of a wound is important to the outcome. Treatment of wounds or other tissue with reduced pressure may be commonly referred to as “negative-pressure therapy,” but is also known by other names, including “negative-pressure wound therapy,” “reduced-pressure therapy,” “vacuum therapy,” “vacuum-assisted closure,” and “topical negative-pressure,” for example. Negative-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.
- There is also widespread acceptance that debridement of a tissue site can be highly beneficial for new tissue growth. Debridement may refer to a process for removing dead, damaged, or infected tissue from a tissue site for improving the healing potential of healthy tissue remaining at the tissue site. Several factors may make proper debridement difficult, such as challenging wound locations, immobile patients, and environmental constraints. Further, debridement may often be painful for the patient, and in some circumstances may also require a high level of skill from the caregiver, thereby presenting additional challenges. Additionally, debridement methods that are less painful to patients may be relatively slow processes. Therefore, improvements to debridement devices, systems, and methods that may reduce the amount of time to debride a tissue site as well as reduce the risks of pain for the patient or damage to healthy tissue associated with conventional methodologies may be desirable.
- New and useful systems, apparatuses, and methods for debriding a tissue site are set forth in the appended claims. Illustrative embodiments are also provided to enable a person skilled in the art to make and use the claimed subject matter.
- In some embodiments, a system for treating a tissue site may include a dressing, a negative-pressure source fluidly coupled to the dressing, a fluid source, and an ultrasonic bubble generator. The ultrasonic bubble generator may be fluidly coupled to the fluid source and to the dressing and may be configured to generate micro-bubbles and ultrasonic waves in a fluid from the fluid source.
- In other embodiments, a method for debriding necrotic tissue from a tissue site may include coupling a fluid source to the tissue site, supplying a fluid from the fluid source to an ultrasonic bubble generator, generating micro-bubbles and ultrasonic waves in the fluid with the ultrasonic bubble generator, and delivering the micro-bubbles and ultrasonic waves to the necrotic tissue. The ultrasonic bubble generator may further include an ultra-violet light source. In some embodiments, the method may further include coupling a negative-pressure source to a dressing.
- Other aspects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.
-
FIG. 1 is a schematic diagram of an example embodiment of negative-pressure therapy system that can deliver ultrasonically-activated micro-bubbles in accordance with this specification; and -
FIG. 2 is a perspective view illustrating additional details that may be associated with some example embodiments of the negative-pressure therapy system ofFIG. 1 . - The following description of example embodiments provides information that enables a person skilled in the art to make and use the subject matter set forth in the appended claims, but may omit certain details already well-known in the art. The following detailed description is, therefore, to be taken as illustrative and not limiting.
- The example embodiments may also be described herein with reference to spatial relationships between various elements or to the spatial orientation of various elements depicted in the attached drawings. In general, such relationships or orientation assume a frame of reference consistent with or relative to a patient in a position to receive treatment. However, as should be recognized by those skilled in the art, this frame of reference is merely a descriptive expedient rather than a strict prescription.
- Referring now primarily to
FIG. 1 , atherapy system 100 that can provide negative-pressure therapy with instillation of topical treatment solutions for treating atissue site 102 is presented. Thetissue site 102 may include, without limitation, any irregularity with a tissue, such as an open wound, surgical incision, or diseased tissue. Thetherapy system 100 is presented in the context of atissue site 102 that includes awound 104, which is through theepidermis 106, or generally skin, and thedermis 108 and reaching into a hypodermis, orsubcutaneous tissue 110. Thetherapy system 100 may be used to treat a wound of any depth, as well as many different types of wounds including open wounds or other tissue sites. Thetissue site 102 may be the bodily tissue of any human, animal, or other organism, including bone tissue, adipose tissue, muscle tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, ligaments, or any other tissue. Treatment of thetissue site 102 may include removal of fluids, for example, exudate or ascites. - The term “tissue site” in this context broadly refers to a wound or defect located on or within tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. A wound may include chronic, acute, traumatic, subacute, and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps, and grafts, for example. The term “tissue site” may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it may be desirable to add or promote the growth of additional tissue. For example, negative pressure may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another tissue location.
- As used herein, the terms “debride,” “debriding,” and “debridement,” relate to the act of removing or the removal of undesirable tissue, such as, eschar, necrotic, damaged, infected, contaminated, or adherent tissue, or foreign material from a tissue site. Several methods of debridement may be employed to treat a
wound 104 havingnecrotic tissue 112, including surgical debridement, mechanical debridement, chemical or enzymatic debridement, and autolytic debridement. - However, each of these methods has both advantages and disadvantages. For example, while mechanical debridement is perhaps the fastest method of debridement, it is almost invariably painful or at least submits the patient to a significant level of discomfort. Additionally, mechanical debridement typically requires a high level of skill from the caregiver.
- Chemical, or enzymatic, debridement entails the use of chemical enzymes to convert the necrotic tissue to slough. Chemical debridement may be fast-acting and cause minimal damage to healthy tissue if the chemicals are applied properly. However, chemical debridement has disadvantages as well. The process may be expensive and traditional chemical debridement methods and systems, such as low pH systems, may be painful to a patient. Other debriding agents, such as papain, may have other health implications and only have limited usage that is restricted by law. Other agents may be used, such as medical grade honey, but can become quickly mobile in the presence of fluid, such as wound exudate, and an applied negative pressure.
- Autolytic debridement, or autolysis, entails the use of the body's own enzymes and white blood cells, along with moisture, to hydrate and liquefy the
necrotic tissue 112 and slough. Since autolytic debridement is a naturally occurring process, it is relatively painless and does not risk damage to healthy tissue. Further, autolytic debridement does not require wound fluid to remain in contact with thenecrotic tissue 112, and can be facilitated by the use of films, hydrocolloids, and hydrogels. A disadvantage of autolytic debridement is that autolytic debridement is slower than other types of debridement, rendering the wound susceptible to infection. - Thus, there is a need for a debriding process that accelerates, and thereby enhances, the naturally-occurring debridement process without the disadvantages associated with mechanical debridement, while also not using enzymes or other chemicals or drugs. Moreover, it is desirable to have a system and method that allow negative-pressure treatment to occur. As disclosed herein, the
therapy system 100 may address these outstanding needs and others. For example, thetherapy system 100 may provide a low-pain alternative for enhanced debridement and healing of wounds that can be used in conjunction with negative-pressure treatment. - Referring again to
FIG. 1 , thewound 104 may includenecrotic tissue 112, and in many instances, it may be desirable to remove thenecrotic tissue 112 in order to promote healing of thewound 104. The illustrative, non-limiting embodiment shows thetherapy system 100 in the context of thewound 104 having a localized, or discrete area, ofnecrotic tissue 112 within the wound. Thetherapy system 100 may be used in broader contexts, including with any tissue site having undesirable tissue. Such undesirable tissue may include, necrotic, damaged, infected, contaminated, or adherent tissue, foreign material within thewound 104, and may include a layer ofnecrotic tissue 112 that covers the entire surface of thewound 104. - The
therapy system 100 may include a dressing, a negative-pressure source, a fluid source, and a micro-bubble source. For example, a dressing 114 may be fluidly coupled to a negative-pressure source 116, afluid source 117, and amicro-bubble subsystem 118, as illustrated inFIG. 1 . Thetherapy system 100 may also include a container for supplying fluid as well as collecting exudates, such as acontainer 120, coupled to the dressing 114 and to the negative-pressure source 116. - In general, components of the
therapy system 100 may be coupled directly or indirectly. For example, the negative-pressure source 116 may be directly coupled to components of themicro-bubble subsystem 118 and thecontainer 120, and indirectly coupled to the dressing 114 through themicro-bubble subsystem 118 and thecontainer 120. In some embodiments, components may be coupled by virtue of physical proximity, being integral to a single structure, or being formed from the same piece of material. Coupling may also include mechanical, thermal, electrical, or chemical coupling (such as a chemical bond) in some contexts. - Components may also be fluidly coupled to each other to provide a path for transferring fluids (i.e., liquid and/or gas) between the components. In some embodiments, for example, components may be fluidly coupled through a tube. A “tube,” as used herein, broadly refers to a tube, pipe, hose, conduit, or other fluid conductor with one or more lumina adapted to convey fluid between two ends. Typically, a tube is an elongated, cylindrical structure with some flexibility, but the geometry and rigidity may vary. A fluid conductor may also be integrally molded into a component in some embodiments.
- The dressing 114 may be placed within, over, on, or otherwise proximate to the
tissue site 102. The dressing 114 may be sealed to tissue near thetissue site 102. For example, the dressing 114 may be sealed to undamaged epidermis peripheral to thetissue site 102. Thus, the dressing 114 can provide a sealed therapeutic environment proximate to thetissue site 102, substantially isolated from the external environment, and the negative-pressure source 116 can reduce the pressure in the sealed therapeutic environment. Negative pressure applied across thetissue site 102 through the dressing 114 in the sealed therapeutic environment can induce macro-strain and micro-strain in the tissue site, as well as remove exudate and other fluid from thetissue site 102, which can be collected in thecontainer 120. - The fluid mechanics of using a negative-pressure source to reduce pressure in another component or location, such as within a sealed therapeutic environment, can be mathematically complex. However, the basic principles of fluid mechanics applicable to negative-pressure therapy and instillation are generally well-known to those skilled in the art.
- In general, fluid flows toward lower pressure along a fluid path. Thus, the term “downstream” typically implies something in a fluid path relatively closer to a source of negative pressure or further away from a source of positive pressure; conversely, the term “upstream” implies something relatively further away from a source of negative pressure or closer to a source of positive pressure. Similarly, it may be convenient to describe certain features in terms of fluid “inlet” or “outlet” in such a frame of reference, and the process of reducing pressure may be described illustratively herein as “delivering,” “distributing,” or “generating” reduced pressure, for example. This orientation is generally presumed for purposes of describing various features and components herein.
- “Negative pressure” generally refers to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment external to a sealed therapeutic environment provided by the dressing 114. In many cases, the local ambient pressure may also be the atmospheric pressure at which a tissue site is located. Alternatively, negative pressure may be a pressure less than a hydrostatic pressure associated with tissue at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Similarly, references to increases in negative pressure typically refer to a decrease in absolute pressure, while decreases in negative pressure typically refer to an increase in absolute pressure.
- A negative-pressure source, such as the negative-
pressure source 116, may be a reservoir of air at a negative pressure, or may be a manual or electrically-powered device that can reduce the pressure in a sealed volume, such as a vacuum pump, a suction pump, a wall suction port available at many healthcare facilities, or a micro-pump, for example. A negative-pressure source may be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate negative-pressure therapy. While the amount and nature of negative pressure applied to a tissue site may vary according to therapeutic requirements, the pressure is generally a low vacuum, also commonly referred to as a rough vacuum, between −5 mm Hg (−667 Pa) and −500 mm Hg (−66.7 kPa). Common therapeutic ranges are between −75 mm Hg (−9.9 kPa) and −300 mm Hg (−39.9 kPa). - The
fluid source 117 may be housed within or used in conjunction with other components to facilitate movement of a fluid. Thefluid source 117 may be a fluid pump, for example a peristaltic pump. Alternatively, in some embodiments, thefluid source 117 may be a fluid reservoir, which may store and deliver fluid. In any embodiment, thefluid source 117, such as a fluid pump or a fluid reservoir, may include a container, such as a canister, pouch, or other storage component. In some embodiments thefluid source 117 may be a fluid pump that helps supply themicro-bubble subsystem 118 with the fluid that may ultimately be delivered to a tissue site. - The dressing 114 may include a manifold 122 and a
drape 124. The dressing 114 may also include anattachment device 126 that affixes thedrape 124 to theepidermis 106 of the patient. Thedrape 124 may also include an adhesive surface that seals directly against theepidermis 106 of the patient without the need for an attachment device. The manifold 122 may be positioned between a tissue-facing surface of thedrape 124 and thetissue site 102. - The manifold 122 may generally include any substance or structure providing a plurality of pathways adapted to collect or distribute fluid across a tissue site. For example, a manifold may be adapted to receive negative pressure from a source and distribute negative pressure through multiple apertures across a tissue site, which may have the effect of collecting fluid from across a tissue site and drawing the fluid toward the source. In some embodiments, the fluid path may be reversed or a secondary fluid path may be provided to facilitate distributing fluid across a tissue site.
- In some illustrative embodiments, the pathways of a manifold may be interconnected to improve distribution or collection of fluids across a tissue site. For example, cellular foam, open-cell foam, reticulated foam, porous tissue collections, and other porous material such as gauze or felted mat generally include pores, edges, and/or walls adapted to form interconnected fluid pathways. Liquids, gels, and other foams may also include or be cured to include apertures and fluid pathways. In some illustrative embodiments, a manifold may be a porous foam material having interconnected cells or pores adapted to distribute negative pressure across a tissue site. The foam material may be either hydrophobic or hydrophilic. The pore size of a foam material may vary according to needs of a prescribed therapy. For example, in some embodiments, the manifold 122 may include a wound filler, which may be a foam having a large pore size or may be a perforated felted foam. The pores or perforations of the wound filler may be in the range of 3-7 millimeters (mm) in diameter, and preferably about 5 mm in diameter. The tensile strength of the manifold 122 may also vary according to needs of a prescribed therapy. For example, the tensile strength of a foam may be increased for instillation of topical treatment solutions. In one non-limiting example, the manifold 122 may be an open-cell, reticulated polyurethane foam such as GranuFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Tex.; in other embodiments the manifold 122 may be an open-cell, reticulated polyurethane foam such as a VeraFlo® foam, also available from Kinetic Concepts, Inc., of San Antonio, Tex.
- In an example in which the manifold 122 may be made from a hydrophilic material, the manifold 122 may also wick fluid away from a tissue site, while continuing to distribute negative pressure to the tissue site. The wicking properties of the manifold 122 may draw fluid away from a tissue site by capillary flow or other wicking mechanisms. An example of a hydrophilic foam is a polyvinyl alcohol, open-cell foam such as V.A.C. WhiteFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Tex. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.
- In some embodiments, the manifold 122 may be constructed from bioresorbable materials. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, and capralactones. The manifold 122 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the manifold 122 to promote cell-growth. A scaffold is generally a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.
- In some embodiments, the
drape 124 may provide a bacterial barrier and protection from physical trauma. Thedrape 124 may also be constructed from a material that can reduce evaporative losses and provide a fluid seal between two components or two environments, such as between a therapeutic environment and a local external environment. Thedrape 124 may be, for example, an elastomeric film or membrane that can provide a seal adequate to maintain a negative pressure at a tissue site for a given negative-pressure source. In some example embodiments, thedrape 124 may be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquid. Such drapes typically have a thickness in the range of 25-50 microns. For permeable materials, the permeability generally should be low enough that a desired negative pressure may be maintained. - In some embodiments, an
attachment device 126 may be used to attach thedrape 124 to an attachment surface, such as undamaged epidermis, a gasket, or another cover. Theattachment device 126 may take many forms. For example, an attachment device may be a medically-acceptable, pressure-sensitive adhesive that extends about a periphery, a portion, or theentire drape 124. In some embodiments, for example, some or all of thedrape 124 may be coated with an acrylic adhesive having a coating weight between 25-65 grams per square meter (g.s.m.). Thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve the seal and reduce leaks. Other example embodiments of an attachment device may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, or organogel. - The negative pressure provided by the negative-
pressure source 116 may be delivered through aconduit 128 to a negative-pressure interface 130, which may be anelbow port 132. In one illustrative embodiment, the negative-pressure interface 130 is a T.R.A.C.® Pad or Sensa T.R.A.C.® Pad available from KCI of San Antonio, Tex. The negative-pressure interface 130 allows the negative pressure to be delivered to thedrape 124 and realized within an interior portion of thedrape 124 and themanifold 122. In this illustrative, non-limiting embodiment, theelbow port 132 extends through thedrape 124 to the manifold 122, but numerous arrangements are possible. - The
container 120 is representative of a container, canister, pouch, or other storage component, which can be used to manage exudate and other fluid withdrawn from a tissue site. In many environments, a rigid container may be preferred or required for collecting, storing, and disposing of fluid. In some preferred embodiments, thecontainer 120 may be positioned in fluid communication between the negative-pressure source 116 and the dressing 114 to collect fluid drawn from a tissue site. Thecontainer 120 may also include features that enable filtering of the effluent that is withdrawn from the dressing 114 andtissue site 102. In some embodiments, thecontainer 120 may attach to the negative-pressure source 116, as illustrated inFIG. 1 . - The
container 120 may include multiple ports and connection interfaces for integration with the negative-pressure source 116, thefluid source 117, and the other components of thetherapy system 100. For example, thecontainer 120 may have two outlets, one of which may be for fluidly connecting thecontainer 120 to thefluid source 117, and the second of which may be for fluidly connecting thecontainer 120 to the negative-pressure source 116. - The
micro-bubble subsystem 118 may include a UVlight sterilizer 136 and anultrasonic bubble generator 138. The UVlight sterilizer 136 may be positioned in fluid connection between the negative-pressure source 116 and theultrasonic bubble generator 138. In some embodiments, themicro-bubble subsystem 118 may be fluidly connected to the negative-pressure source 116 and the dressing 114 by thesupply conduit 140. In some embodiments, themicro-bubble subsystem 118 may be in close physical proximity to the dressing 114, or optionally incorporated as part of thedressing 114. In other embodiments, some or all of the components of themicro-bubble subsystem 118 may be incorporated within the negative-pressure source 116. - As fluid is moved from the negative-
pressure source 116 through thesupply conduit 140 to theultrasonic bubble generator 138, the fluid may pass through the UVlight sterilizer 136. The UVlight sterilizer 136 may contain a UV light source, which may dose the fluid passing through the UVlight sterilizer 136 with UV light to kill any pathogens that may be in the fluid. Once the fluid has passed through the UVlight sterilizer 136, the fluid may be delivered to theultrasonic bubble generator 138 throughsupply conduit 140. - The
ultrasonic bubble generator 138 may function to generate both micro-bubbles and an ultrasonic waveform in a fluid. For example, theultrasonic bubble generator 138 may be an apparatus for generating an output flow of liquid, including an acoustic transducer for introducing acoustic energy into the liquid and a gas bubble generator for generating gas bubbles within the liquid, as described in U.S. Patent Application Publication No. US 2012/0227761 A1, which is hereby incorporated by reference in its entirety. As illustrated inFIG. 1 , fluid may be delivered from the UVlight sterilizer 136 throughsupply conduit 140 to theultrasonic bubble generator 138. As the fluid passes through theultrasonic bubble generator 138, theultrasonic bubble generator 138 may generate and inject gas bubbles within the fluid. While the micro-bubbles may be generated in a range of sizes, the micro-bubbles may typically be approximately 15-200 micrometers (μm) in diameter. Theultrasonic bubble generator 138 may then generate an ultrasonic waveform that may be conducted through the fluid as it flows through theultrasonic bubble generator 138. In some embodiments, theultrasonic bubble generator 138 may include a transducer that emits acoustic energy. The acoustic energy may be emitted as intermittent pulses. Referring also toFIG. 2 , asmicro-bubbles 202 are hit by the ultrasonic waves, the micro-bubbles may undergo significant deformation which may manifest itself as aripple 204 at the gas/liquid interface. As a result of this ripple, the micro-bubble can exert a scrubbing action on surfaces it touches as the micro-bubble 206 is deformed, and the turbulence formed around the micro-bubble may also cause the micro-bubble to be drawn to surfaces and into cracks and crevices, such as deformities at a tissue site. - In some embodiments, the manifold 122 may be tailored to cause minimal attenuation of the ultrasonic energy generated by the
micro-bubble source 118. For example, the manifold 122 may be largely constructed from polymers that are hydrophilic, which may contain water or be configured to absorb water. Such hydrophilic polymers may include poly hydroxy ethyl methacrylate, copolymer of N-vinyl pyrrolidone and 2-hydroxy ethyl methacrylate, terpolymer based on glycerol methacrylate, copolymer of N-vinyl pyrrolidone and methyl methacrylate, as well as polymethyl methacrylate (PMMA). Additionally, the manifold 122 may be constructed from hydrophilic polyurethane polymers, such as TECOPHILIC hydrophilic polyurethanes available from The Lubrizol Corp. of Wickliffe, Ohio, which in extrusion grade formulations, may absorb water up to 100% of the weight of dry resin (900% of weight of dry resin for hydrogel grades) while retaining structural integrity. In some embodiments, the manifold 122 may be formed from one of the hydrophilic polymers listed above into a porous or foamed structure with pores measuring approximately 5-10 mm in diameter, which may minimize the number of struts that could interfere with the passage of bubbles. In other embodiments, the manifold 122 may be formed from one of the hydrophilic polymers formed into a perforated sheet having protrusions on one side. In some instances, the protrusions may be spaced about 5-10 mm apart from each other, and may be hemispherical or polygonal in shape. The protrusions may act as spacers between thewound 104 and thedrape 124. - The
therapy system 100 presented inFIG. 1 may also include a second interface, such as fluid-delivery interface 142. The fluid-delivery interface 142 may be fluidly coupled to the dressing 114 and may pass through a hole cut in thedrape 124. The hole cut in the drape for the fluid-delivery interface 142 may be separated as far apart as possible from the location or other hole cut in the drape through which the negative-pressure interface 130 may pass. The fluid-delivery interface 142 may allow for a fluid to be delivered by thetherapy system 100 through thedrape 124 and to the manifold 122 and thetissue site 102. - In some embodiments, the fluid-
delivery interface 142 may include an inlet pad. The inlet pad may be a non-dampening material or a material that is not sound-absorbing. In some embodiments, the inlet pad may be an elastomer. For example, the inlet pad may be an elastic polymer, such as polyurethane, thermoplastic elastomers, polyether block amide (PEBAX), polyisoprene, polychloroprene, chlorosulphonated polythene, and polyisobutylene, blends and copolymers. - The composition of the fluid may vary according to a prescribed therapy, but examples of solutions that may be suitable for some prescriptions include a saline solution with a low level of surfactant, such as <0.1%, and more typically 0.015%. Such surfactants may include Pluronic F68, polyolefin oxides, and polyolefin glycols. By including a surfactant in the fluid, the generated micro-bubbles may be preserved for a longer duration as they travel from the
ultrasonic bubble generator 138 to thetissue site 102. - The
therapy system 100 may also include aparticulate filter 134, which may be positioned in fluid communication between thecontainer 120 and/or the negative-pressure source 116 and thedressing 114. Theparticulate filter 134 may function to remove particulate matter from the effluent that has circulated through the dressing 114. For example, in the embodiment pictured inFIG. 1 , fluid delivered to the dressing 114 and to thetissue site 102 may be drawn out of the dressing 114 through the negative-pressure interface 130 and transported through negative-pressure conduit 128 to theparticulate filter 134. The fluid may be filtered to remove particulate matter in theparticulate filter 134, before being recollected in thecontainer 120. - In operation, the negative-
pressure source 116 may pump fluid, such as a saline solution through thesupply conduit 140 to a UV light sterilization unit, such as UVlight sterilizer 136. Once the fluid has passed through the UVlight sterilizer 136, the fluid may continue throughsupply conduit 140 to theultrasonic bubble generator 138, where micro-bubbles may be generated in the fluid, followed by the fluid and micro-bubbles being activated by ultrasonic energy applied by theultrasonic bubble generator 138. The activated fluid may then pass through the fluid-delivery interface 142 and into thedressing 114. The activated fluid may then pass through the manifold 122 and reach thewound 104, where the activated fluid may debridenecrotic tissue 112. - Following the debridement of the
necrotic tissue 112 by the activated fluid, the remaining effluent may be drawn out of the dressing 114 by negative pressure applied to the dressing 114 andtissue site 102 by the negative-pressure source 116. For example, the effluent may be drawn from thewound 104, through the manifold 122, and out of the dressing 114 through the negative-pressure interface 130. The effluent may then pass through negative-pressure conduit 128 to theparticulate filter 134, where particulate matter may be filtered out of the effluent. The filtered fluid may then be collected by thecontainer 120 before being recirculated by the negative-pressure source 116 through the UVlight sterilizer 136 andultrasonic bubble generator 138 to thewound 104. - The systems, apparatuses, and methods described herein may provide significant advantages. For example, a therapy system described above may provide a low-pain, clean method to achieve an alternative form of mechanical debridement. The therapy system can keep a wound enclosed, thus reducing the possible risk of infection, and can also store any particulate matter in a convenient location that may be easily disposed. The therapy system may also reduce the risk of contaminating the environment external to a wound with potentially infectious matter, and can also keep odors contained.
- While shown in a few illustrative embodiments, a person having ordinary skill in the art will recognize that the systems, apparatuses, and methods described herein are susceptible to various changes and modifications. Moreover, descriptions of various alternatives using terms such as “or” do not require mutual exclusivity unless clearly required by the context, and the indefinite articles “a” or “an” do not limit the subject to a single instance unless clearly required by the context.
- The appended claims set forth novel and inventive aspects of the subject matter described above, but the claims may also encompass additional subject matter not specifically recited in detail. For example, certain features, elements, or aspects may be omitted from the claims if not necessary to distinguish the novel and inventive features from what is already known to a person having ordinary skill in the art. Features, elements, and aspects described herein may also be combined or replaced by alternative features serving the same, equivalent, or similar purpose without departing from the scope of the invention defined by the appended claims.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/091,149 US20230147519A1 (en) | 2015-05-08 | 2022-12-29 | Wound debridement by irrigation with ultrasonically activated microbubbles |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562158630P | 2015-05-08 | 2015-05-08 | |
US15/147,666 US10471190B2 (en) | 2015-05-08 | 2016-05-05 | Wound debridement by irrigation with ultrasonically activated microbubbles |
US16/595,763 US11565033B2 (en) | 2015-05-08 | 2019-10-08 | Wound debridement by irrigation with ultrasonically activated microbubbles |
US18/091,149 US20230147519A1 (en) | 2015-05-08 | 2022-12-29 | Wound debridement by irrigation with ultrasonically activated microbubbles |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/595,763 Continuation US11565033B2 (en) | 2015-05-08 | 2019-10-08 | Wound debridement by irrigation with ultrasonically activated microbubbles |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230147519A1 true US20230147519A1 (en) | 2023-05-11 |
Family
ID=56080461
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/147,666 Active 2038-01-06 US10471190B2 (en) | 2015-05-08 | 2016-05-05 | Wound debridement by irrigation with ultrasonically activated microbubbles |
US16/595,763 Active 2038-03-10 US11565033B2 (en) | 2015-05-08 | 2019-10-08 | Wound debridement by irrigation with ultrasonically activated microbubbles |
US18/091,149 Pending US20230147519A1 (en) | 2015-05-08 | 2022-12-29 | Wound debridement by irrigation with ultrasonically activated microbubbles |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/147,666 Active 2038-01-06 US10471190B2 (en) | 2015-05-08 | 2016-05-05 | Wound debridement by irrigation with ultrasonically activated microbubbles |
US16/595,763 Active 2038-03-10 US11565033B2 (en) | 2015-05-08 | 2019-10-08 | Wound debridement by irrigation with ultrasonically activated microbubbles |
Country Status (3)
Country | Link |
---|---|
US (3) | US10471190B2 (en) |
EP (1) | EP3294158B1 (en) |
WO (1) | WO2016182861A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
CA2819549C (en) | 2010-12-08 | 2019-09-10 | Convatec Technologies Inc. | Wound exudate system accessory |
US10207031B2 (en) | 2010-12-08 | 2019-02-19 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
US9168179B2 (en) * | 2011-06-24 | 2015-10-27 | Kci Licensing, Inc. | Reduced-pressure dressings employing tissue-fixation elements |
GB201115182D0 (en) | 2011-09-02 | 2011-10-19 | Trio Healthcare Ltd | Skin contact material |
GB2497406A (en) | 2011-11-29 | 2013-06-12 | Webtec Converting Llc | Dressing with a perforated binder layer |
CN105008611A (en) | 2012-12-20 | 2015-10-28 | 康沃特克科技公司 | Processing of chemically modified cellulosic fibres |
USD832999S1 (en) * | 2015-05-05 | 2018-11-06 | Medaxis Ag | Pump for debridement by water jet |
BR112018070238A2 (en) | 2016-03-30 | 2019-01-29 | Acib Gmbh | detection of microbial wound infection |
JP7183146B2 (en) | 2016-03-30 | 2022-12-05 | コンバテック・テクノロジーズ・インコーポレイテッド | Detection of microbial infection in wounds |
BR112019000301A2 (en) | 2016-07-08 | 2019-04-16 | Convatec Technologies Inc. | flexible negative pressure system |
CN109640904A (en) | 2016-07-08 | 2019-04-16 | 康沃特克科技公司 | Fluid collection device |
JP6975770B2 (en) | 2016-07-08 | 2021-12-01 | コンバテック・テクノロジーズ・インコーポレイテッドConvatec Technologies Inc | Fluid flow sensing |
US11554205B2 (en) * | 2017-01-10 | 2023-01-17 | Medela Holding Ag | Appliance and method for wound therapy by means of negative pressure and delivery of a substance |
EP3606573B1 (en) * | 2017-04-04 | 2021-08-25 | 3M Innovative Properties Company | Apparatuses, systems, and methods for the treatment of a tissue site with negative pressure and oxygen |
US20200197318A1 (en) * | 2017-05-22 | 2020-06-25 | The Regents Of The University Of California | Micro/nanobubble solutions for tissue preservation and generation thereof |
GB2563212B (en) * | 2017-06-05 | 2020-01-08 | Sloan Water Tech Limited | Cleaning, healing and regeneration of tissue and wounds |
US11918549B2 (en) | 2017-08-25 | 2024-03-05 | AZ Solutions LLC | System and method for wound treatment and irrigation |
US10960129B2 (en) * | 2017-08-25 | 2021-03-30 | AZ Solutions LLC | System and method for patient skin treatment and irrigation |
US20210077671A1 (en) * | 2018-03-29 | 2021-03-18 | Kci Licensing, Inc. | Wound therapy system with wound volume estimation |
CN113301874A (en) * | 2019-01-24 | 2021-08-24 | 凯希特许有限公司 | Variable density dressing |
US11491054B2 (en) * | 2019-02-06 | 2022-11-08 | Kci Licensing, Inc. | Wound therapy system with internal alternating orifice |
US20210154403A1 (en) * | 2019-11-25 | 2021-05-27 | Thomas Leroy Schmitz | Joint capsule fluid delivery |
US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
US11141528B1 (en) | 2020-12-14 | 2021-10-12 | Thomas Leroy Schmitz | Therapeutic fluid delivery cartridge |
US11806222B2 (en) * | 2021-08-06 | 2023-11-07 | John Baeke | Apparatus for cutting a material and a method for cutting a negative pressure wound therapy dressing |
WO2024074919A1 (en) * | 2022-10-06 | 2024-04-11 | Solventum Intellectual Properties Company | Negative pressure wound therapy canisters |
Family Cites Families (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1355846A (en) | 1920-02-06 | 1920-10-19 | David A Rannells | Medical appliance |
US2547758A (en) | 1949-01-05 | 1951-04-03 | Wilmer B Keeling | Instrument for treating the male urethra |
US2632443A (en) | 1949-04-18 | 1953-03-24 | Eleanor P Lesher | Surgical dressing |
GB692578A (en) | 1949-09-13 | 1953-06-10 | Minnesota Mining & Mfg | Improvements in or relating to drape sheets for surgical use |
US2682873A (en) | 1952-07-30 | 1954-07-06 | Johnson & Johnson | General purpose protective dressing |
NL189176B (en) | 1956-07-13 | 1900-01-01 | Hisamitsu Pharmaceutical Co | PLASTER BASED ON A SYNTHETIC RUBBER. |
US2969057A (en) | 1957-11-04 | 1961-01-24 | Brady Co W H | Nematodic swab |
US3066672A (en) | 1960-09-27 | 1962-12-04 | Jr William H Crosby | Method and apparatus for serial sampling of intestinal juice |
US3367332A (en) | 1965-08-27 | 1968-02-06 | Gen Electric | Product and process for establishing a sterile area of skin |
US3520300A (en) | 1967-03-15 | 1970-07-14 | Amp Inc | Surgical sponge and suction device |
US3568675A (en) | 1968-08-30 | 1971-03-09 | Clyde B Harvey | Fistula and penetrating wound dressing |
US3682180A (en) | 1970-06-08 | 1972-08-08 | Coilform Co Inc | Drain clip for surgical drain |
BE789293Q (en) | 1970-12-07 | 1973-01-15 | Parke Davis & Co | MEDICO-SURGICAL DRESSING FOR BURNS AND SIMILAR LESIONS |
US3826254A (en) | 1973-02-26 | 1974-07-30 | Verco Ind | Needle or catheter retaining appliance |
DE2527706A1 (en) | 1975-06-21 | 1976-12-30 | Hanfried Dr Med Weigand | DEVICE FOR THE INTRODUCTION OF CONTRAST AGENTS INTO AN ARTIFICIAL INTESTINAL OUTLET |
DE2640413C3 (en) | 1976-09-08 | 1980-03-27 | Richard Wolf Gmbh, 7134 Knittlingen | Catheter monitor |
NL7710909A (en) | 1976-10-08 | 1978-04-11 | Smith & Nephew | COMPOSITE STRAPS. |
GB1562244A (en) | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
US4080970A (en) | 1976-11-17 | 1978-03-28 | Miller Thomas J | Post-operative combination dressing and internal drain tube with external shield and tube connector |
US4139004A (en) | 1977-02-17 | 1979-02-13 | Gonzalez Jr Harry | Bandage apparatus for treating burns |
US4184510A (en) | 1977-03-15 | 1980-01-22 | Fibra-Sonics, Inc. | Valued device for controlling vacuum in surgery |
US4165748A (en) | 1977-11-07 | 1979-08-28 | Johnson Melissa C | Catheter tube holder |
US4256109A (en) | 1978-07-10 | 1981-03-17 | Nichols Robert L | Shut off valve for medical suction apparatus |
SE414994B (en) | 1978-11-28 | 1980-09-01 | Landstingens Inkopscentral | VENKATETERFORBAND |
GB2047543B (en) | 1978-12-06 | 1983-04-20 | Svedman Paul | Device for treating tissues for example skin |
US4266545A (en) | 1979-04-06 | 1981-05-12 | Moss James P | Portable suction device for collecting fluids from a closed wound |
US4284079A (en) | 1979-06-28 | 1981-08-18 | Adair Edwin Lloyd | Method for applying a male incontinence device |
US4261363A (en) | 1979-11-09 | 1981-04-14 | C. R. Bard, Inc. | Retention clips for body fluid drains |
US4569348A (en) | 1980-02-22 | 1986-02-11 | Velcro Usa Inc. | Catheter tube holder strap |
US4480638A (en) | 1980-03-11 | 1984-11-06 | Eduard Schmid | Cushion for holding an element of grafted skin |
US4297995A (en) | 1980-06-03 | 1981-11-03 | Key Pharmaceuticals, Inc. | Bandage containing attachment post |
US4333468A (en) | 1980-08-18 | 1982-06-08 | Geist Robert W | Mesentery tube holder apparatus |
US4465485A (en) | 1981-03-06 | 1984-08-14 | Becton, Dickinson And Company | Suction canister with unitary shut-off valve and filter features |
US4392853A (en) | 1981-03-16 | 1983-07-12 | Rudolph Muto | Sterile assembly for protecting and fastening an indwelling device |
US4373519A (en) | 1981-06-26 | 1983-02-15 | Minnesota Mining And Manufacturing Company | Composite wound dressing |
US4392858A (en) | 1981-07-16 | 1983-07-12 | Sherwood Medical Company | Wound drainage device |
US4419097A (en) | 1981-07-31 | 1983-12-06 | Rexar Industries, Inc. | Attachment for catheter tube |
AU550575B2 (en) | 1981-08-07 | 1986-03-27 | Richard Christian Wright | Wound drainage device |
SE429197B (en) | 1981-10-14 | 1983-08-22 | Frese Nielsen | SAR TREATMENT DEVICE |
DE3146266A1 (en) | 1981-11-21 | 1983-06-01 | B. Braun Melsungen Ag, 3508 Melsungen | COMBINED DEVICE FOR A MEDICAL SUCTION DRAINAGE |
US4551139A (en) | 1982-02-08 | 1985-11-05 | Marion Laboratories, Inc. | Method and apparatus for burn wound treatment |
US4475909A (en) | 1982-05-06 | 1984-10-09 | Eisenberg Melvin I | Male urinary device and method for applying the device |
EP0100148B1 (en) | 1982-07-06 | 1986-01-08 | Dow Corning Limited | Medical-surgical dressing and a process for the production thereof |
NZ206837A (en) | 1983-01-27 | 1986-08-08 | Johnson & Johnson Prod Inc | Thin film adhesive dressing:backing material in three sections |
US4548202A (en) | 1983-06-20 | 1985-10-22 | Ethicon, Inc. | Mesh tissue fasteners |
US4540412A (en) | 1983-07-14 | 1985-09-10 | The Kendall Company | Device for moist heat therapy |
US4543100A (en) | 1983-11-01 | 1985-09-24 | Brodsky Stuart A | Catheter and drain tube retainer |
US4525374A (en) | 1984-02-27 | 1985-06-25 | Manresa, Inc. | Treating hydrophobic filters to render them hydrophilic |
GB2157958A (en) | 1984-05-03 | 1985-11-06 | Ernest Edward Austen Bedding | Ball game net support |
US4897081A (en) | 1984-05-25 | 1990-01-30 | Thermedics Inc. | Percutaneous access device |
US5215522A (en) | 1984-07-23 | 1993-06-01 | Ballard Medical Products | Single use medical aspirating device and method |
GB8419745D0 (en) | 1984-08-02 | 1984-09-05 | Smith & Nephew Ass | Wound dressing |
US4872450A (en) | 1984-08-17 | 1989-10-10 | Austad Eric D | Wound dressing and method of forming same |
US4655754A (en) | 1984-11-09 | 1987-04-07 | Stryker Corporation | Vacuum wound drainage system and lipids baffle therefor |
US4826494A (en) | 1984-11-09 | 1989-05-02 | Stryker Corporation | Vacuum wound drainage system |
US4605399A (en) | 1984-12-04 | 1986-08-12 | Complex, Inc. | Transdermal infusion device |
US5037397A (en) | 1985-05-03 | 1991-08-06 | Medical Distributors, Inc. | Universal clamp |
US4640688A (en) | 1985-08-23 | 1987-02-03 | Mentor Corporation | Urine collection catheter |
US4710165A (en) | 1985-09-16 | 1987-12-01 | Mcneil Charles B | Wearable, variable rate suction/collection device |
US4758220A (en) | 1985-09-26 | 1988-07-19 | Alcon Laboratories, Inc. | Surgical cassette proximity sensing and latching apparatus |
US4733659A (en) | 1986-01-17 | 1988-03-29 | Seton Company | Foam bandage |
WO1987004626A1 (en) | 1986-01-31 | 1987-08-13 | Osmond, Roger, L., W. | Suction system for wound and gastro-intestinal drainage |
US4838883A (en) | 1986-03-07 | 1989-06-13 | Nissho Corporation | Urine-collecting device |
JPS62281965A (en) | 1986-05-29 | 1987-12-07 | テルモ株式会社 | Catheter and catheter fixing member |
GB8621884D0 (en) | 1986-09-11 | 1986-10-15 | Bard Ltd | Catheter applicator |
GB2195255B (en) | 1986-09-30 | 1991-05-01 | Vacutec Uk Limited | Apparatus for vacuum treatment of an epidermal surface |
US4743232A (en) | 1986-10-06 | 1988-05-10 | The Clinipad Corporation | Package assembly for plastic film bandage |
DE3634569A1 (en) | 1986-10-10 | 1988-04-21 | Sachse Hans E | CONDOM CATHETER, A URINE TUBE CATHETER FOR PREVENTING RISING INFECTIONS |
JPS63135179A (en) | 1986-11-26 | 1988-06-07 | 立花 俊郎 | Subcataneous drug administration set |
GB8628564D0 (en) | 1986-11-28 | 1987-01-07 | Smiths Industries Plc | Anti-foaming agent suction apparatus |
GB8706116D0 (en) | 1987-03-14 | 1987-04-15 | Smith & Nephew Ass | Adhesive dressings |
US4787888A (en) | 1987-06-01 | 1988-11-29 | University Of Connecticut | Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a) |
US4863449A (en) | 1987-07-06 | 1989-09-05 | Hollister Incorporated | Adhesive-lined elastic condom cathether |
US5176663A (en) | 1987-12-02 | 1993-01-05 | Pal Svedman | Dressing having pad with compressibility limiting elements |
US4906240A (en) | 1988-02-01 | 1990-03-06 | Matrix Medica, Inc. | Adhesive-faced porous absorbent sheet and method of making same |
US4985019A (en) | 1988-03-11 | 1991-01-15 | Michelson Gary K | X-ray marker |
GB8812803D0 (en) | 1988-05-28 | 1988-06-29 | Smiths Industries Plc | Medico-surgical containers |
US4919654A (en) | 1988-08-03 | 1990-04-24 | Kalt Medical Corporation | IV clamp with membrane |
US5000741A (en) | 1988-08-22 | 1991-03-19 | Kalt Medical Corporation | Transparent tracheostomy tube dressing |
US5059596A (en) | 1989-01-16 | 1991-10-22 | Roussel Uclaf | Azabicyclo compounds |
GB8906100D0 (en) | 1989-03-16 | 1989-04-26 | Smith & Nephew | Laminates |
US5100396A (en) | 1989-04-03 | 1992-03-31 | Zamierowski David S | Fluidic connection system and method |
US5527293A (en) | 1989-04-03 | 1996-06-18 | Kinetic Concepts, Inc. | Fastening system and method |
US5261893A (en) | 1989-04-03 | 1993-11-16 | Zamierowski David S | Fastening system and method |
US4969880A (en) | 1989-04-03 | 1990-11-13 | Zamierowski David S | Wound dressing and treatment method |
US5358494A (en) | 1989-07-11 | 1994-10-25 | Svedman Paul | Irrigation dressing |
JP2719671B2 (en) | 1989-07-11 | 1998-02-25 | 日本ゼオン株式会社 | Wound dressing |
US5232453A (en) | 1989-07-14 | 1993-08-03 | E. R. Squibb & Sons, Inc. | Catheter holder |
GB2235877A (en) | 1989-09-18 | 1991-03-20 | Antonio Talluri | Closed wound suction apparatus |
US5134994A (en) | 1990-02-12 | 1992-08-04 | Say Sam L | Field aspirator in a soft pack with externally mounted container |
US5092858A (en) | 1990-03-20 | 1992-03-03 | Becton, Dickinson And Company | Liquid gelling agent distributor device |
US5149331A (en) | 1991-05-03 | 1992-09-22 | Ariel Ferdman | Method and device for wound closure |
US5278100A (en) | 1991-11-08 | 1994-01-11 | Micron Technology, Inc. | Chemical vapor deposition technique for depositing titanium silicide on semiconductor wafers |
US5636643A (en) | 1991-11-14 | 1997-06-10 | Wake Forest University | Wound treatment employing reduced pressure |
US5645081A (en) | 1991-11-14 | 1997-07-08 | Wake Forest University | Method of treating tissue damage and apparatus for same |
US5279550A (en) | 1991-12-19 | 1994-01-18 | Gish Biomedical, Inc. | Orthopedic autotransfusion system |
US5167613A (en) | 1992-03-23 | 1992-12-01 | The Kendall Company | Composite vented wound dressing |
FR2690617B1 (en) | 1992-04-29 | 1994-06-24 | Cbh Textile | TRANSPARENT ADHESIVE DRESSING. |
DE4306478A1 (en) | 1993-03-02 | 1994-09-08 | Wolfgang Dr Wagner | Drainage device, in particular pleural drainage device, and drainage method |
US6241747B1 (en) | 1993-05-03 | 2001-06-05 | Quill Medical, Inc. | Barbed Bodily tissue connector |
US5342376A (en) | 1993-05-03 | 1994-08-30 | Dermagraphics, Inc. | Inserting device for a barbed tissue connector |
US5344415A (en) | 1993-06-15 | 1994-09-06 | Deroyal Industries, Inc. | Sterile system for dressing vascular access site |
US5437651A (en) | 1993-09-01 | 1995-08-01 | Research Medical, Inc. | Medical suction apparatus |
US5549584A (en) | 1994-02-14 | 1996-08-27 | The Kendall Company | Apparatus for removing fluid from a wound |
US5556375A (en) | 1994-06-16 | 1996-09-17 | Hercules Incorporated | Wound dressing having a fenestrated base layer |
US5607388A (en) | 1994-06-16 | 1997-03-04 | Hercules Incorporated | Multi-purpose wound dressing |
US5664270A (en) | 1994-07-19 | 1997-09-09 | Kinetic Concepts, Inc. | Patient interface system |
DK0853950T3 (en) | 1994-08-22 | 2002-11-25 | Kinetic Concepts Inc | Wound drainage canisters |
DE29504378U1 (en) | 1995-03-15 | 1995-09-14 | Mtg Medizinisch Tech Geraeteba | Electronically controlled low-vacuum pump for chest and wound drainage |
GB9523253D0 (en) | 1995-11-14 | 1996-01-17 | Mediscus Prod Ltd | Portable wound treatment apparatus |
US6135116A (en) | 1997-07-28 | 2000-10-24 | Kci Licensing, Inc. | Therapeutic method for treating ulcers |
GB9719520D0 (en) | 1997-09-12 | 1997-11-19 | Kci Medical Ltd | Surgical drape and suction heads for wound treatment |
AU755496B2 (en) | 1997-09-12 | 2002-12-12 | Kci Licensing, Inc. | Surgical drape and suction head for wound treatment |
US6071267A (en) | 1998-02-06 | 2000-06-06 | Kinetic Concepts, Inc. | Medical patient fluid management interface system and method |
US6488643B1 (en) | 1998-10-08 | 2002-12-03 | Kci Licensing, Inc. | Wound healing foot wrap |
US6287316B1 (en) | 1999-03-26 | 2001-09-11 | Ethicon, Inc. | Knitted surgical mesh |
US6856821B2 (en) | 2000-05-26 | 2005-02-15 | Kci Licensing, Inc. | System for combined transcutaneous blood gas monitoring and vacuum assisted wound closure |
US7799004B2 (en) | 2001-03-05 | 2010-09-21 | Kci Licensing, Inc. | Negative pressure wound treatment apparatus and infection identification system and method |
US6991643B2 (en) | 2000-12-20 | 2006-01-31 | Usgi Medical Inc. | Multi-barbed device for retaining tissue in apposition and methods of use |
ATE266443T1 (en) | 2000-02-24 | 2004-05-15 | Venetec Int Inc | UNIVERSAL CATHETER FASTENING SYSTEM |
IL137689A0 (en) | 2000-08-03 | 2001-10-31 | L R Res & Dev Ltd | System for enhanced chemical debridement |
US6916296B2 (en) * | 2000-11-20 | 2005-07-12 | Soring Gmbh Medizintechnik | System for antiseptic surgery |
US6540705B2 (en) | 2001-02-22 | 2003-04-01 | Core Products International, Inc. | Ankle brace providing upper and lower ankle adjustment |
US7846141B2 (en) | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
US7367342B2 (en) * | 2002-12-02 | 2008-05-06 | Life Support Technologies, Inc. | Wound management systems and methods for using the same |
GB0325126D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus with heat |
GB0325120D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus with actives |
US7909805B2 (en) | 2004-04-05 | 2011-03-22 | Bluesky Medical Group Incorporated | Flexible reduced pressure treatment appliance |
US8529548B2 (en) | 2004-04-27 | 2013-09-10 | Smith & Nephew Plc | Wound treatment apparatus and method |
US7967763B2 (en) | 2005-09-07 | 2011-06-28 | Cabochon Aesthetics, Inc. | Method for treating subcutaneous tissues |
US20080195036A1 (en) | 2005-12-02 | 2008-08-14 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
CA2633910C (en) * | 2006-01-23 | 2012-07-03 | Kci Licensing, Inc. | System and method for treating a wound using ultrasonic debridement |
WO2008064502A1 (en) * | 2006-11-30 | 2008-06-05 | Medela Holding Ag | Device for treating wounds |
US8021347B2 (en) | 2008-07-21 | 2011-09-20 | Tyco Healthcare Group Lp | Thin film wound dressing |
US8007481B2 (en) | 2008-07-17 | 2011-08-30 | Tyco Healthcare Group Lp | Subatmospheric pressure mechanism for wound therapy system |
US8251979B2 (en) | 2009-05-11 | 2012-08-28 | Tyco Healthcare Group Lp | Orientation independent canister for a negative pressure wound therapy device |
US8216198B2 (en) | 2009-01-09 | 2012-07-10 | Tyco Healthcare Group Lp | Canister for receiving wound exudate in a negative pressure therapy system |
US8708984B2 (en) * | 2008-12-24 | 2014-04-29 | Kci Licensing, Inc. | Reduced-pressure wound treatment systems and methods employing manifold structures |
KR20110117129A (en) | 2008-12-31 | 2011-10-26 | 케이씨아이 라이센싱 인코포레이티드 | Systems for providing fluid flow to tissues |
GB2472998A (en) | 2009-08-26 | 2011-03-02 | Univ Southampton | Cleaning using acoustic energy and gas bubbles |
US8591486B2 (en) * | 2010-11-17 | 2013-11-26 | Kci Licensing, Inc. | Reduced-pressure systems and methods employing an ultraviolet light source for reducing bioburden |
CN110448407B (en) * | 2012-07-16 | 2022-08-09 | 史密夫和内修有限公司 | Negative pressure wound closure device |
-
2016
- 2016-05-05 US US15/147,666 patent/US10471190B2/en active Active
- 2016-05-05 EP EP16725004.2A patent/EP3294158B1/en active Active
- 2016-05-05 WO PCT/US2016/031070 patent/WO2016182861A1/en active Application Filing
-
2019
- 2019-10-08 US US16/595,763 patent/US11565033B2/en active Active
-
2022
- 2022-12-29 US US18/091,149 patent/US20230147519A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2016182861A1 (en) | 2016-11-17 |
US20160325028A1 (en) | 2016-11-10 |
EP3294158A1 (en) | 2018-03-21 |
US20200046888A1 (en) | 2020-02-13 |
EP3294158B1 (en) | 2020-05-06 |
US11565033B2 (en) | 2023-01-31 |
US10471190B2 (en) | 2019-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11565033B2 (en) | Wound debridement by irrigation with ultrasonically activated microbubbles | |
US20230201042A1 (en) | Hybrid drape having a gel-coated perforated mesh | |
US20190192750A1 (en) | Hybrid Sealing Tape | |
US20180353334A1 (en) | Tissue Contact Interface | |
US10143485B2 (en) | Debriding dressing for use with negative pressure and fluid instillation | |
EP3876885B1 (en) | Wound dressing with semi-rigid support to increase disruption using perforated dressing and negative pressure wound therapy | |
CN106413594B (en) | Destructive dressing for use with negative pressure and fluid instillation | |
JP5547197B2 (en) | Multilayer dressing, system, and method for applying reduced pressure to a tissue site | |
US11083884B2 (en) | Apparatus for negative-pressure therapy and irrigation | |
US20240099898A1 (en) | Dressing with protruding layer allowing for cleansing of wound bed macro deformations | |
US20200000643A1 (en) | Long-Duration, Deep Wound Filler With Means To Prevent Granulation In-Growth | |
US11259528B2 (en) | System and methods for treatment of wounds with negative pressure and peroxy pyruvic acid | |
US11878106B2 (en) | System and methods for the treatment of wounds with negative pressure and instillation of peroxide pyruvic acid | |
CN111954510A (en) | Dressing for disrupting debris at a tissue site | |
US20220249291A1 (en) | Antimicrobial/antibacterial disruptive dressing for use with negative pressure and fluid instillation | |
WO2020197883A1 (en) | System and methods for the treatment of wounds with negative pressure and instillation of peroxide pyruvic acid | |
CN116669670A (en) | Prolonged wearing dressing with clean holes for preserved beancurd |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: 3M INNOVATIVE PROPERTIES COMPANY, MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KCI LICENSING, INC.;REEL/FRAME:064788/0823 Effective date: 20230830 |
|
AS | Assignment |
Owner name: 3M INNOVATIVE PROPERTIES COMPANY, MINNESOTA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION LISTED ON SCHEDULE OF IP RIGHTS ATTACHED TO ASSIGNMENT AT LINES 55: 71; 89; 116-129; AND 131 NEED TO BE DELETED PREVIOUSLY RECORDED AT REEL: 064788 FRAME: 0823. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:KCI LICENSING, INC.;REEL/FRAME:064886/0479 Effective date: 20230830 |
|
AS | Assignment |
Owner name: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY, MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:3M INNOVATIVE PROPERTIES COMPANY;REEL/FRAME:066438/0301 Effective date: 20240201 |